Ground-breaking Ceremony for Sartorius Stedim Cellca

Share This.....Share on LinkedInTweet about this on TwitterShare on FacebookShare on Google+Email this to someone
  • Biopharma equipment supplier builds laboratory and office facility at Science Park III in Ulm, Germany
  • Cell Culture Technology Center will cost around 30 million euros

 

Goettingen/Ulm, Germany, September 28, 2017 – Sartorius Stedim Cellca is building a new 30-million-euro Cell Culture Technology Center at Science Park III in Eselsberg situated at the northwestern scientific hub of the city of Ulm, Germany. Hugo de Wit, Managing Director, and Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG, symbolically broke ground in the presence of around 100 guests, marking the official start of construction work. “This is a significant step for Sartorius Stedim Cellca and our staff to soon be able to work in an advanced new complex. We are very proud of this as the new, modern facility will enable us to continue accommodating the growing needs of our customers in the future as well,” said de Wit.

So far, Sartorius Stedim Cellca has been working in a rented building in Laupheim. The new laboratory and office complex will approximately double the company’s space and is scheduled to be completed by the end of 2019. In addition, relocation to this zone will provide closer proximity to universities and research institutes that are based in Ulm’s Science Park. In addition, this move to the new facility, which is conveniently accessible by various transportation routes between the large cities of Stuttgart and Munich, will make it even easier for international customers to visit the company. Sartorius Stedim Cellca purchased the property of more than 6,000 square meters at Science Park III back in November 2016 and can therefore expand its Cell Culture Technology Center by a further 5,000 square meters as needed.

Sartorius Stedim Cellca develops cell lines and protein production processes, licenses technologies for the production of proteins and offers cell culture media. Proteins produced by living cells under controlled conditions are primarily used in the development and manufacture of medications. The company has been a part of the biopharma equipment supplier Sartorius Stedim Biotech since 2015 and currently employs around 90 people. Over the medium term, the company plans to extend its workforce to more than 120 people.